DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives.
M Monnot,O Mauffret,Violaine Simon,E Lescot,B Psaume,JM Saucier,Monique Charra,Jr J Belehradek,S Fermandjian +8 more
115
TL;DR: Structural-activity relationships indicated that a change in nitrogen atom position in the pyridinic ring greatly affected drug effects both on topoisomerase II action and cytotoxicity to L1210 cells.
read more
About: This article is published in Journal of Biological Chemistry. The article was published on 25 Jan 1991. and is currently open access. The article focuses on the topics: Topoisomerase & DNA damage.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Catalytic topoisomerase II inhibitors in cancer therapy.
TL;DR: A review of catalytic topoisomerase II poisons can be found in this paper, with an emphasis on therapeutically used compounds, such as Baccelli and novobiocin.
399
The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
TL;DR: The DNA adduct formation described is a novel mechanism for the ellipticine action and might in part explain its tumor specificity.
160
Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
TL;DR: In this paper, the authors characterized the interaction between ellipticine and yeast topoisomerase II using steady-state and frequency domain fluorescence spectroscopy, and showed that the enzyme dictates the ionic state of the drug in the ternary complex.
137
DNA topoisomerase I and II as targets for rational design of new anticancer drugs
Jeffrey Cummings,John F. Smyth +1 more
TL;DR: New classes of inhibitor have recently been described with novel mechanisms of action including compounds which do not stabilize cleavable complexes or bind significantly to DNA, which may prove to be more selective and less toxic.
127
The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells
TL;DR: The molecular mechanisms of ellipticine's apoptotic action in human breast MCF-7 cancer cells were due to cell cycle arrest and induction of apoptosis, triggering of Fas/Fas ligand pathway, disruption of mitochondrial function, and the apoptotic signaling was amplified by cross-talk between Fas death receptor and mitochondrial apoptotic pathway.
121
References
DNA topoisomerase poisons as antitumor drugs.
TL;DR: Inhibition of DNA Synthesis, Inhibition of Cell Division, and Other CELLULAR RESPONSes and DRUG RESISTANCE are studied.
1.9K
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
TL;DR: In studies in vitro, mammalian DNA topoisomerase II mediates DNA damage by adriamycin and other related antitumor drugs, and has been shown to induce single- and double-strand breaks in DNA.
1.5K
Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide
TL;DR: The agreement between in vitro and in vivo studies suggests that mammalian DNA topoisomerase II may be the primary target of m-AMSA and that the drug-induced complex formation between topoisomersase II and DNA may beThe cause of cytotoxicity and other effects such as DNA sequence rearrangements and sister-chromatid exchange.
587